九州通(600998.SH)與華海醫藥就“厄貝沙坦片”簽訂《戰略合作框架協議》
格隆匯11月25日丨九州通(600998.SH)公佈,公司與浙江華海藥業股份有限公司控股子公司浙江華海醫藥銷售有限公司(以下簡稱“華海醫藥”)於2019年11月25日簽署《戰略合作框架協議》,華海醫藥將其在國家組織帶量採購試點擴圍中的中標品種“厄貝沙坦片”在除4+7帶量採購城市及福建、河北醫院之外的全渠道銷售,全部委託給公司,公司將發揮廣泛的市場優勢資源及市場推廣能力,配合華海醫藥進行渠道搭建及管控,提升該中標產品在“4+7”帶量採購城市及福建、河北醫院之外的全渠道覆蓋,並保障“厄貝沙坦片”在聯盟採購中選省份的醫療配送。
“厄貝沙坦片”的適應症為治療原發性高血壓、合併高血壓的2型糖尿病腎病,在“4+7”城市藥品集中採購擬中標數量為1.37億片(含75mg及150mg規格),本次華海醫藥委託公司在“4+7”帶量採購城市及福建、河北醫院之外的全渠道銷售目標為9億片(含聯盟地區藥品集中採購中標數量)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.